Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Sold by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC lowered its stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 69.4% during the fourth quarter, Holdings Channel reports. The firm owned 122,424 shares of the company’s stock after selling 277,042 shares during the period. Jasper Therapeutics makes up approximately 2.2% of Ally Bridge Group NY LLC’s investment portfolio, making the stock its 19th largest position. Ally Bridge Group NY LLC’s holdings in Jasper Therapeutics were worth $2,617,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Jane Street Group LLC acquired a new stake in Jasper Therapeutics during the 3rd quarter worth $251,000. Barclays PLC increased its position in shares of Jasper Therapeutics by 320.7% during the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after purchasing an additional 12,308 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Jasper Therapeutics by 239.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock valued at $308,000 after purchasing an additional 11,567 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Jasper Therapeutics by 12.6% in the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock valued at $316,000 after purchasing an additional 1,652 shares during the period. Finally, Simplify Asset Management Inc. purchased a new position in Jasper Therapeutics during the 4th quarter worth approximately $428,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on JSPR. Royal Bank of Canada decreased their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. UBS Group started coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $38.00 target price for the company. Finally, JMP Securities restated a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research report on Monday, January 6th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics has an average rating of “Buy” and an average price target of $62.50.

Jasper Therapeutics Trading Down 2.0 %

NASDAQ JSPR opened at $5.38 on Friday. The stock has a market capitalization of $80.82 million, a price-to-earnings ratio of -1.14 and a beta of 2.55. The business’s 50 day moving average is $4.77 and its two-hundred day moving average is $12.16. Jasper Therapeutics, Inc. has a 12-month low of $3.13 and a 12-month high of $26.84.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.35). Equities analysts forecast that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.